Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.

7 stock ideas from top global brokerages

ET Bureau|
CREDIT SUISSE ON ADANI PORT
1/8

CREDIT SUISSE ON ADANI PORT

>> Maintains Outperform Rating, Target at Rs 480/share
>> Reiterates Outperform on strong growth
>> Coal & crude decline; container growth reasonable
>> Growth driven by Dhamra and Katupalli

PTI
CREDIT SUISSE ON LUPIN
2/8

CREDIT SUISSE ON LUPIN

>> Maintains Outperform Rating, Target at Rs 850/share
>> Attractive deal for Japan business
>> This frees up capital & management bandwidth for US & India
>> Stock has multiple catalysts for FY21
>> Transaction is EPS accretive

CITI ON BRITANNIA
3/8

CITI ON BRITANNIA

>> Maintains Outperform Rating, Target at Rs 3,575/share
>> Q2 Profits ahead of estimates
>> Revise EPS estimates by 9-10% over FY20-22E
>> Maintains Buy with a new Target at Rs 3575/share

PTI
MORGAN STANLEY ON NARAYANA HRUDAYALAYA
4/8

MORGAN STANLEY ON NARAYANA HRUDAYALAYA

>> Maintain Overweight, Target at Rs 349/share
>> Co has improved underlying earnings power over last 3-4 years
>> Co has expanded bed capacity through geographic diversification
>> Losses are narrowing in these new centers
>> Expects mature facilities give steady growth visibility

PTI
NOMURA ON SUN TV
5/8

NOMURA ON SUN TV

>> Maintains BUY rating, Target Rs 689/share
>> Near-term ad-slowdown impacting Q2
>> See subscription growth story intact
>> Sun likely to be a key beneficiary of digitisation

Shutterstock.com
CLSA ON LUPIN
6/8

CLSA ON LUPIN

>> Signing of a definitive agreement with Unison Capital to divest its entire 99.82% stake in Japanese subsidiary Kyowa
>> Balance sheet strengthened but US pipeline remains thin; Maintain SELL
>> Maintains SELL Rating, target price Rs 650
>> Management also alluded that it is looking at M&A opportunities
>> Transaction will be EPS-accretive and values Kyowa at an EV of Rs37bn

PTI
CLSA ON COAL INDIA
7/8

CLSA ON COAL INDIA

>> Sharp decline in volume in recent months
>> Earnings outlook muted but valuation attractive for its low risk profile
>> Retains BUY recommendation and Rs270 target price

PTI
CLSA ON INDIAN PHARMA
8/8

CLSA ON INDIAN PHARMA

>> Multiplier effect from power brands to help sustain MNC momentum
>> Power brands and new launches to drive growth
>> Better placed to withstand policy disruption
>> Initiates on Abbott India with a BUY rating, target Rs 14,500

Shutterstock.com
X
User

Other useful Links


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service